The Food and Drug Administration approved Keytruda to treat patients with recurrent or metastatic cutaneous squamous cell carcinoma that cannot be treated with surgery or radiation.
The Food and Drug Administration on Wednesday approved Keytruda (pembrolizumab) to treat patients with recurrent or metastatic cutaneous squamous cell carcinoma that cannot be treated with surgery or radiation.
The agency based its decision on data from the open-label, multicenter KEYNOTE-629 trial, which demonstrated an objective response rate (the proportion of complete and partial responses to treatment) of 34% in patients who received Keytruda. A median duration of response was not reached in the trial.
Patients received Keytruda at 200 milligrams (mg) intravenously every three weeks until their disease either progressed, they reached unacceptable toxicity, or they reached a maximum of 24 months on therapy.
Side effects in the KEYNOTE-629 trial were comparable to those that have occurred in other clinical trials where patients also received Keytruda. The most common side effects included but were not limited to, fatigue, decreased appetite, diarrhea, rash, cough, constipation and pain.
The FDA's approval includes two different dosing options. Patients can either receive Keytruda 200 mg intravenously every three weeks or Keytruda 400 mg every six weeks.
Check back later for what you need to know about this approval.
MLB VP Reveals Cancer Diagnosis, Jaxon-Smith Njigba Raises Awareness for Cancer Foundation and More
December 8th 2023As Billy Bean, MLB VP, revealed a cancer diagnosis and Toronto Blue Jays sportscaster, Jamie Campbell showed pre-skin cancer photo, here is what’s happening in the oncology space this week.
Read More
Savoring Every Ounce of Life While Undergoing Treatment for Skin Cancer
January 14th 2021In this episode of the “CURE Talks Cancer” podcast, we spoke with someone who has undergone 41 surgeries and physically debilitating treatments during his more than 15-year journey with several cases of skin cancer. We discussed his cancer journey, and why, as he starts a new treatment after his most prior therapy failed, he’s focused on quality rather than quantity of life.
Listen